Table 2.
Adverse effects.
| Parameter | FLOT | SOX |
|---|---|---|
| WBC decreased | ||
| Grade 0, 1, 2 | 30 (96.8) | 24 (100.0) |
| Grade 3, 4 | 1 (3.2) | 0 |
| Neutrophil count decreased | ||
| Grade 0, 1, 2 | 29 (93.5) | 22 (91.7) |
| Grade 3, 4 | 2 (6.5) | 2 (8.3) |
| Febrile neutropenia | ||
| Grade 0, 1, 2 | 31 (100.0) | 23 (95.8) |
| Grade 3, 4 | 0 | 1 (4.2) |
| Anemia | ||
| Grade 0, 1, 2 | 27 (87.1) | 22 (91.7) |
| Grade 3, 4 | 4 (12.9) | 2 (8.3) |
| Platelet count decreased | ||
| Grade 0, 1, 2 | 30 (96.8) | 24 (100.0) |
| Grade 3, 4 | 1 (3.2) | 0 |
| Aminotrasferase increased | ||
| Grade 0, 1, 2 | 30 (96.8) | 24 (100.0) |
| Grade 3, 4 | 1 (3.2) | 0 |
| Nausea | ||
| Grade 0, 1, 2 | 30 (96.8) | 24 (100.0) |
| Grade 3, 4 | 1 (3.2) | 0 |
| Vomiting | ||
| Grade 0, 1, 2 | 30 (96.8) | 24 (100.0) |
| Grade 3, 4 | 1 (3.2) | 0 |
| Diarrhea | ||
| Grade 0, 1, 2 | 31 (100.0) | 24 (100.0) |
| Grade 3, 4 | 0 | 0 |
| Peripheral neuropathy | ||
| Grade 0, 1, 2 | 31 (100.0) | 24 (100.0) |
| Grade 3, 4 | 0 | 0 |
| Fatigue | ||
| Grade 0, 1, 2 | 31 (100.0) | 24 (100.0) |
| Grade 3, 4 | 0 | 0 |
| Anorexia | ||
| Grade 0, 1, 2 | 30 (96.8) | 24 (100.0) |
| Grade 3, 4 | 1 (3.2) | 0 |
| Oral mucositis | ||
| Grade 0, 1, 2 | 31 (100.0) | 24 (100.0) |
| Grade 3, 4 | 0 | 0 |
Analysis of per-protocol population except otherwise indicated.